Hypertension and cardiac arrhythmias: executive summary of a consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLEACE)

Lip G. Y. H., Coca A., Kahan T., Boriani G., Manolis A. S., Olsen M. H., ...More

EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, vol.3, no.4, pp.235-250, 2017 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 3 Issue: 4
  • Publication Date: 2017
  • Doi Number: 10.1093/ehjcvp/pvx019
  • Journal Name: EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.235-250
  • Keywords: Hypertension, Atrial fibrillation, Arrhythmias, Left ventricular hypertrophy, LEFT-VENTRICULAR HYPERTROPHY, ATRIAL-FIBRILLATION PATIENTS, ADDITIONAL RISK-FACTOR, HIGH BLOOD-PRESSURE, STROKE PREVENTION, COST-EFFECTIVENESS, CARDIOVASCULAR MORBIDITY, ANTITHROMBOTIC THERAPY, ORAL ANTICOAGULANTS, CATHETER ABLATION
  • Eskisehir Osmangazi University Affiliated: Yes

Abstract

Hypertension (HTN) is a common cardiovascular risk factor leading to heart failure (HF), coronary artery disease (CAD), stroke, peripheral artery disease and chronic renal failure. Hypertensive heart disease can manifest as many types of cardiac arrhythmias, most commonly being atrial fibrillation (AF). Both supraventricular and ventricular arrhythmias may occur in HTN patients, especially in those with left ventricular hypertrophy (LVH), CAD, or HF. In addition, high doses of thiazide diuretics commonly used to treat HTN, may result in electrolyte abnormalities (e.g. hypokalaemia, hypomagnesaemia), contributing further to arrhythmias, while effective blood pressure control may prevent the development of the arrhythmias such as AF.